Omeros Corporation

Omeros Corporation swung to a second-quarter profit, reporting net income of $13.23 million, or $0.18 per share, compared with a net loss of $25.42 million, or $0.43 per share, a year earlier. Net revenue was $28.55 million, driven by YARTEMLEA sales of $32.2 million, which grew 190% from the first quarter of 2026. The company plans to begin enrollment by the end of 2026 in two YARTEMLEA studies, one for hyperinflammatory acute respiratory distress syndrome and another for prophylactic use in pediatric patients with predictably severe transplant-associated thrombotic microangiopathy. Omeros is also initiating a nonclinical study for OMS527 in response to an FDA request and targets a first-in-human Phase 1b trial for OMS805 in late 2027. Shares rose 0.81% to $13.71 in regular trading and surged 15.85% to $15.61 in the overnight market.

AstraZeneca reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core earnings per share rose 18% at constant exchange rates to $2.63, ahead of the $2.48 consensus, while total revenue reached $15.38 billion, up 5% at constant exchange rates. Oncology revenue grew 16% to $7.33 billion, driven by Tagrisso, Imfinzi, and Enhertu, and Rare Disease contributed $4.9 billion, offsetting a 15% decline in the Cardiovascular, Renal & Metabolism segment due to Farxiga's loss of exclusivity in the U.S. and China pricing pressures. Management expressed confidence in reaching its $80 billion total revenue target by 2030 despite near-term headwinds. Separately, a Phase 3 study of Ultomiris in hematopoietic stem cell transplant-associated thrombotic microangiopathy failed to meet its primary endpoint, which H.C. Wainwright called a positive for competitor Omeros.

Gossamer Bio plans to submit a New Drug Application for Seralutinib to treat pulmonary arterial hypertension in September 2026, while Forte Biosciences has agreed to be acquired by argenx for $77 per share in cash, representing a total equity value of roughly $2.2 billion. Gossamer also regained worldwide rights to Seralutinib from Chiesi and reported cash of approximately $57 million as of June 30, 2026. Entera Bio shares soared over 90% after announcing an oversubscribed private placement expected to generate about $275 million in gross proceeds. Omeros gained more than 15% after AstraZeneca's Ultomiris failed a Phase 3 trial for HSCT-TMA, removing a key competitive threat to Omeros's YARTEMLEA. First Tracks Biotherapeutics rose over 18%, continuing its strong performance since its April 2026 Nasdaq debut.

Omeros shares climbed roughly 12% on Monday after AstraZeneca's Ultomiris failed a phase 3 trial for transplant-associated thrombotic microangiopathy, a rare disorder involving blood clots and small-vessel damage. Omeros markets Yartemlea, which is approved for hematopoietic stem cell transplant–associated thrombotic microangiopathy. HC Wainwright analyst Brandon Folkes, who rates Omeros a buy, said the setback removes the cleanest near-term competitive overhang on Yartemlea and meaningfully lowers the probability of a near-term on-label adult C5 competitor disrupting its US launch.

NovoCure and Omeros present two distinct investment cases in the emerging pharmaceutical space. NovoCure, which markets Tumor Treating Fields devices for cancer, reported fiscal 2025 revenue of nearly $655.4 million, an 8.3% increase, but posted a net loss of roughly $136.2 million and negative free cash flow of $75.7 million. Omeros is transitioning to a commercial-stage company following the late 2025 FDA approval of Yartemlea for TA-TMA, and it reported first-quarter 2026 sales of $9.89 million along with net income of $56.06 million, boosted by upfront payments from a partnership with Novo Nordisk. NovoCure trades at a price-to-sales ratio of 2.4 times, while Omeros carries a much higher multiple of 74.3 times. Analysts project NovoCure will not generate free cash flow until fiscal 2028, whereas Omeros is expected to reach profitability by 2028, making it a potentially safer long-term bet despite its premium valuation.

Omeros is favored over Intellia Therapeutics as the better biotech stock to buy in 2026, according to a Motley Fool analysis. Intellia, a clinical-stage CRISPR gene-editing company, reported a net loss of roughly $412.7 million on revenue of approximately $67.7 million in fiscal 2025, with its lead program nex-z facing a clinical hold after a patient death. Omeros, transitioning to commercial stage after the FDA approval of Yartemlea for TA-TMA, posted first-quarter 2026 sales of $9.89 million and net income of $56.06 million, boosted by upfront payments from its partnership with Novo Nordisk. While Intellia holds promise with a potential HAE treatment approval in early 2027, its early-stage pipeline and deep projected losses through 2029 present higher risk. Omeros, despite trading at a premium valuation, offers firm initial sales, a healthy balance sheet, and a path to near-term profitability, making it the safer choice.